Skip to Main Content

Advertisement intended for health care professionals

American Society of Hematology Logo Open Menu
Cart
header search
Search
Skip Nav Destination

On Location

Updates from major medical meetings in the field of hematology/oncology
Next-Gen BCL2 Inhibitor Sonrotoclax Shows Good Outcomes in Phase I Trial Free
Thomas R. Collins
December 2, 2025
Zanubrutinib, Obinutuzumab, Sonrotoclax Combo Shows Positive Outcomes for Treatment-Naïve CLL Free
Leah Lawrence
December 2, 2025
Head-To-Head Data Strong for Pirtobrutinib Over Ibrutinib Free
Thomas R. Collins
December 2, 2025
Lisaftoclax Achieves Objective Response Primary Endpoint in Phase II R/R CLL Trial Free
Anna Azvolinsky, PhD
December 2, 2025
BCMA-Targeting CAR T-Cell Therapy May Be Effective in NDMM Free
Leah Lawrence
December 2, 2025
BCMA, CD19 Dual-Targeting FasTCAR-T Cell Therapy Shows 100% Response in NDMM Free
Katie Robinson
December 2, 2025
Benefit Seen for Earlier Cilta-Cel Treatment for Standard-Risk MM Free
Thomas R. Collins
December 2, 2025
Study Offers New Insights Into Optimal Treatment for Frail Patients with Myeloma Free
Lara C. Pullen, PhD
December 2, 2025
Fixed-Duration Targeted Treatment as Effective as BTK Inhibitor Therapy for CLL Free
Lara C. Pullen, PhD
November 26, 2025
Delayed Obinutuzumab Enhances Safety in First-Line Acalabrutinib Plus Venetoclax for CLL Free
Katie Robinson
November 26, 2025
Preclinical Study Shows Potential of Menin Inhibition in Myeloproliferative Neoplasms Free
Katie Robinson
November 26, 2025
BTK Degrader Shows Tolerable Safety, High Responses in Phase I Study of R/R CLL/SLL Free
Katie Robinson
November 26, 2025
Patient-Clinician Treatment Priorities Don’t Always Align in PV Management Free
Leah Lawrence
November 26, 2025
Risk Factors Identified in PV Renal Dysfunction Free
Thomas R. Collins
November 26, 2025
Rusfertide Shows Durable Responses in Phase III Study of Polycythemia Vera Free
Katie Robinson
November 24, 2025
Sapablursen Meets Primary Endpoint for Treatment of Polycythemia Vera Free
Lara C. Pullen, PhD
November 24, 2025
Bomedemstat Effectively Reduced Hematocrit in Phase II Trial of Patients With Previously Treated PV Free
Anna Azvolinsky, PhD
November 24, 2025
Anti-BCMA Anito-Cel CAR-T Offers More Efficient, Stable Therapy Free
Thomas R. Collins
November 24, 2025
Real-World Study of Cesni-Cel in Spain Demonstrates Efficacy on Par With Clinical Trial Results Free
Anna Azvolinsky, PhD
November 24, 2025
Rapid CAR-T Expansion Linked to Delayed Neurotoxicity After Cilta-Cel Infusion in Multiple Myeloma Free
Pinky Sharma
November 24, 2025

Advertisement intended for health care professionals

Connect with us:

CURRENT ISSUE
December 2025

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2025 by American Society of Hematology
 
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals